Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
83°
Partly Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Editas Medicine
(NQ:
EDIT
)
3.870
+0.080 (+2.11%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Editas Medicine
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Top CRISPR Stocks
February 11, 2023
CRISPR is a narrow niche of the biotechnology industry, but it could become the fastest growing and most significant of all the biotech businesses.
Via
Talk Markets
3 No-Brainer Stocks to Buy Right Now for Less Than $25
February 04, 2023
All three healthcare stocks are showing solid long-term potential.
Via
The Motley Fool
Why Editas Medicine's Shares Jumped This Week
February 03, 2023
The gene-editing biotech's shares have had a strong two-week run.
Via
The Motley Fool
Is Editas Medicine Stock a Buy Now?
February 03, 2023
Layoffs and a thin clinical-stage pipeline aren't very encouraging.
Via
The Motley Fool
3 CRISPR Stocks to Buy Now Or You’ll Be Kicking Yourself Later
February 02, 2023
CRISPR stocks are heating back up after a difficult 2022. These three names should be at the top of your watchlist.
Via
InvestorPlace
Why Editas Medicine Stock Charged Higher in January
February 02, 2023
The genome-editing company's shares spiked following a definitive agreement with Shoreline Biosciences last month.
Via
The Motley Fool
Expert Ratings for Editas Medicine
February 01, 2023
Via
Benzinga
Why Shares of Editas Medicine Jumped This Week
January 26, 2023
It's been a seesaw month for the clinical-stage gene-editing biotech.
Via
The Motley Fool
Shoreline Biosciences Acquires Editas' iNK Cell Franchise, Related Gene Editing Technologies
January 19, 2023
Via
Benzinga
Analyst Expectations for Editas Medicine's Future
January 10, 2023
Via
Benzinga
Analyst Initiates Coverage On This Peer Lagging Gene-Editing Stock
February 01, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 1, 2023
February 01, 2023
Via
Benzinga
7 CRISPR Stocks With the Best Long-Term Potential
January 30, 2023
CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve.
Via
InvestorPlace
Why Editas Medicine Stock Is Sliding Today
January 09, 2023
The gene-editing pioneer announced a big shake-up with its research and development programs.
Via
The Motley Fool
Analyst Ratings for Editas Medicine
December 06, 2022
Via
Benzinga
Why Shares of Editas Medicine Dropped 15.5% in November
December 05, 2022
The biotech's shares plummeted after it paused a key clinical trial.
Via
The Motley Fool
How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
January 25, 2023
Five biotechs have already issued layoffs in 2023. Many seem to have good potential, but time will tell if the shifts create the value analysts anticipate.
Via
MarketBeat
Topics
Workforce
Exposures
Layoff
Product Safety
Editas Medicine and Shoreline Biosciences Enter into Definitive Agreement for Shoreline to Acquire Editas’ iNK Cell Franchise and Related Gene Editing Technologies
January 19, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
3 CRISPR Stocks That Will Make You Filthy Rich in 10 Years
January 18, 2023
CRISPR could be revolutionary, leading us to put together this list of CRISPR stocks that will make you rich in 10 years.
Via
InvestorPlace
Editas Medicine Announces Strategic Updates and Portfolio Reprioritization
January 09, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Precigen's Overnight Cell Manufacturing Technology Could Offer Advanced AML Patients The Option Of Promising CAR-T Therapy
December 08, 2022
-Clinical Data Due Next Week at ASH-
Via
Benzinga
2 Beaten-Down Stocks to Watch Closely Next Year
December 06, 2022
These biotechs could skyrocket in 2023, but only if they can execute their plans.
Via
The Motley Fool
Editas Medicine Touts Positive Safety, Efficacy Data From Two Sickle Cell Disease Patients
December 06, 2022
Via
Benzinga
Editas Medicine Announces Positive Safety and Efficacy Data from the First Two Patients Treated in the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease
December 06, 2022
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine to Host Virtual Event to Highlight Initial Clinical Data from the RUBY Trial of EDIT-301 for Severe Sickle Cell Disease
December 01, 2022
From
Editas Medicine, Inc.
Via
GlobeNewswire
Where Will Editas Medicine Be in 1 Year?
November 20, 2022
The company could continue lagging the market for a while.
Via
The Motley Fool
Gene Editing Stock's Prospects Cut In Half By Analyst, Citing Limited Value In Retina Treatment
November 18, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 18, 2022
November 18, 2022
Upgrades
Via
Benzinga
Palo Alto To Surge Around 38%? Plus This Analyst Predicts $65 For Helmerich & Payne
November 18, 2022
Barclays raised the price target on Palo Alto Networks, Inc. (NASDAQ: PANW) from $200 to $215. Barclays analyst Saket Kalia maintained an Overweight rating on the stock. Palo Alto Networks shares fell...
Via
Benzinga
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.